Terms: = Kidney tumors AND RUNX1, PEBP2A2, 861, ENSG00000159216, Q01196, AML1, CBFA2, AMLCR1 AND Diagnosis
12 results:
1. Tumor-Stroma Proportion to Predict Chemoresistance in Patients With Ovarian Cancer.
Lou E; Clemente V; Grube M; Svedbom A; Nelson AC; Blome F; Staebler A; Kommoss S; Bazzaro M
JAMA Netw Open; 2024 Feb; 7(2):e240407. PubMed ID: 38411963
[TBL] [Abstract] [Full Text] [Related]
2. MTAN: A semi-supervised learning model for kidney tumor segmentation.
Sun P; Yang S; Guan H; Mo T; Yu B; Chen Z
J Xray Sci Technol; 2023; 31(6):1295-1313. PubMed ID: 37718833
[TBL] [Abstract] [Full Text] [Related]
3. Clinicopathological characteristics and outcomes of synchronous renal cell carcinoma and urothelial carcinoma: A population-based analysis.
Wu K; Liu X; Wang Y; Wang X; Li X
Front Public Health; 2022; 10():994351. PubMed ID: 36388369
[TBL] [Abstract] [Full Text] [Related]
4. Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer Treatment.
Wallach JD; Deng Y; McCoy RG; Dhruva SS; Herrin J; Berkowitz A; Polley EC; Quinto K; Gandotra C; Crown W; Noseworthy P; Yao X; Shah ND; Ross JS; Lyon TD
JAMA Netw Open; 2021 Oct; 4(10):e2130587. PubMed ID: 34677594
[TBL] [Abstract] [Full Text] [Related]
5. Association of Acute kidney Injury Receiving kidney Replacement Therapy With Prognosis of Critically Ill Patients With and Without Cancer: A Retrospective Study.
Druml W; Zajic P; Schellongowski P; Fellinger T; Metnitz B; Posch M; Metnitz PGH
Crit Care Med; 2021 Nov; 49(11):1932-1942. PubMed ID: 34166290
[TBL] [Abstract] [Full Text] [Related]
6. Genetic profile and immunohistochemical study of clear cell renal carcinoma: Pathological-anatomical correlation and prognosis.
Diez-Calzadilla NA; Noguera Salvá R; Soriano Sarrió P; Martínez-Jabaloyas JM
Cancer Treat Res Commun; 2021; 27():100374. PubMed ID: 33932757
[TBL] [Abstract] [Full Text] [Related]
7. Patterns of Current Cigarette Smoking, Quit Attempts and Cessation Counseling among Survivors of Smoking-Related and Nonsmoking-Related Urological Malignancies: A Nationally Representative Cross-Sectional Analysis.
Matulewicz RS; Basak R; Zambrano I; Dearing BA; Schatz D; El Shahawy O; Sherman S; Bjurlin MA
J Urol; 2021 May; 205(5):1444-1451. PubMed ID: 33347778
[TBL] [Abstract] [Full Text] [Related]
8. PRMT1 expression in renal cell tumors- application in differential diagnosis and prognostic relevance.
Filipović J; Bosić M; Ćirović S; Životić M; Dunđerović D; Đorđević D; Živković-Perišić S; Lipkovski A; Marković-Lipkovski J
Diagn Pathol; 2019 Oct; 14(1):120. PubMed ID: 31655611
[TBL] [Abstract] [Full Text] [Related]
9. The effect of a treatment delay on outcome in metastatic renal cell carcinoma.
Iacovelli R; Galli L; De Giorgi U; Porta C; Nolè F; Zucali P; Sabbatini R; Mosca A; Atzori F; Santini D; Facchini G; Fornarini G; Buti S; Massari F; Masini C; Ricotta R; Biasco E; Lolli C; Gri N; Verri E; Miggiano C; Vitale MG; Tortora G
Urol Oncol; 2019 Aug; 37(8):529.e1-529.e7. PubMed ID: 30935843
[TBL] [Abstract] [Full Text] [Related]
10. Microarray and Proteomic Analyses of Myeloproliferative Neoplasms with a Highlight on the mTOR Signaling Pathway.
Čokić VP; Mossuz P; Han J; Socoro N; Beleslin-Čokić BB; Mitrović O; Subotički T; Diklić M; Leković D; Gotić M; Puri RK; Noguchi CT; Schechter AN
PLoS One; 2015; 10(8):e0135463. PubMed ID: 26275051
[TBL] [Abstract] [Full Text] [Related]
11. Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma.
Suppiah R; Shaheen PE; Elson P; Misbah SA; Wood L; Motzer RJ; Negrier S; Andresen SW; Bukowski RM
Cancer; 2006 Oct; 107(8):1793-800. PubMed ID: 16983701
[TBL] [Abstract] [Full Text] [Related]
12. [Cerebrovascular disease: its relationship with cardiovascular and renal pathology in 134 clinical autopsies].
Arismendi-Morillo GJ; Fernández-Abreu MC; Vilchez-Barrios G; Molina-Viloria OM; Cardozo JJ
Rev Neurol; 2004 Sep 1-15; 39(5):410-4. PubMed ID: 15378451
[TBL] [Abstract] [Full Text] [Related]
